fda warning bpc-157 not approved panel backs compounded BPC-157, KPV peptides in win for RFK Jr 7 peptides under FDA review:

Microdosing GLP-1 or GLP-1/GIP refers to using lower doses of the medication to support long-term health and longevity, rather than for diabetes or weight management

Specifically, the panel will assess whether those substances should be moved off the Category 2 list a designation reserved for bulk drug substances that present potential safety risks and are therefore ineligible for routine compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act

Why Patients Combine BPC-157 with GLP-1 Medications The rationale for this combination goes beyond simple compatibility

The GLOW Blend is frequently studied alongside Epithalon in comprehensive longevity and anti-aging research to investigate combined tissue regeneration and telomere pathway effects

In the cystitis study by Lee et al